Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Neogenomics (NEO) Notes Payables (2024 - 2025)

Neogenomics filings provide 2 years of Notes Payables readings, the most recent being $201.1 million for Q1 2025.

On a quarterly basis, Notes Payables changed N/A to $201.1 million in Q1 2025 year-over-year; TTM through Mar 2025 was $201.1 million, a N/A change, with the full-year FY2024 number at $200.8 million, changed N/A from a year prior.
Notes Payables hit $201.1 million in Q1 2025 for Neogenomics, roughly flat from $200.8 million in the prior quarter.
In the past five years, Notes Payables ranged from a high of $201.1 million in Q1 2025 to a low of $200.1 million in Q2 2024.